Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists.

Area of Science:

• Oncology
• Radiology
• Neuro-oncology

Background:

• Brain metastases from non-small cell lung cancer (NSCLC) management has evolved with expanded systemic therapy options.
• Systemic therapies are now integral to treating metastatic central nervous system (CNS) disease in NSCLC patients.

Purpose of the Study:

• To guide radiologists on the role of systemic therapies in NSCLC brain metastases.
• To focus on tyrosine kinase inhibitors (TKIs) and their impact on CNS disease.
• To review the blood-brain barrier's role and imaging-based response assessment guidelines.

Main Methods:

• Review article synthesizing current literature on systemic therapies for NSCLC brain metastases.
• Discussion of the blood-brain barrier's influence on drug delivery and efficacy.
• Analysis of imaging-based response assessment criteria, specifically Response Assessment in Neuro-Oncology (RANO).

Main Results:

• Systemic therapies, particularly TKIs, are effective adjuncts to surgery and radiation for NSCLC brain metastases.
• Understanding the blood-brain barrier is critical for optimizing systemic treatment strategies.
• Standardized criteria like RANO are essential for evaluating treatment response in neuro-oncology.

Conclusions:

• Radiologists play a key role in managing NSCLC brain metastases treated with systemic therapies.
• Accurate assessment of treatment response using RANO criteria is vital for patient care.
• This review provides a framework for understanding and applying current management strategies.